Apratastat

Drug Profile

Apratastat

Alternative Names: TMI-005

Latest Information Update: 10 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Wyeth
  • Class Anti-inflammatories; Antirheumatics; Morpholines; Small molecules
  • Mechanism of Action Matrix metalloproteinase inhibitors; Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 11 Jul 2005 Data presented at the Annual European Congress of Rheumatology (EULAR-2005) have been added to the adverse events and Rheumatoid Arthritis pharmacodynamics sectionS ,,
  • 16 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in Canada (PO)
  • 16 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top